Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab vs panretinal photocoagulation in proliferative diabetic retinopathy
CTR20210574Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2021
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of brolucizumab in proliferative diabetic retinopathy (PDR), sponsored by Novartis. Started Apr 2021; status: completed.
02
Drugs
brolucizumab
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on CTR20210574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210574.